Moalic-Allain Virginie
Laboratoire de génétique moléculaire et d'histocompatibilité, Pôle de pathologie biologie, CHRU Morvan, Brest.
Ann Biol Clin (Paris). 2014 Mar-Apr;72(2):178-84. doi: 10.1684/abc.2014.0940.
The Luminex technology has become an important tool for HLA antibody screening and identification. This is the most sensitive technology to detect HLA antibodies for transplant patients and patients on awaiting list, and it has ushered a new strategy to determine HLA compatibility between donor and recipient. Moreover, the clinical relevance of all detected anti-HLA antibodies is not well understood, because this technique was shown to be prone to many artefacts or interferences, leading to a complicated interpretation for biologists and clinicians. Our objective in this article is to provide a careful consideration about this solid phase assay, and to focus attention on raised questions about technical performance and interpretation of the results. We should keep in mind that our results could change the clinical management of sensitized patients, their aptitude to receive a graft, and their follow-up.
Luminex技术已成为HLA抗体筛查和鉴定的重要工具。这是检测移植患者和等待移植患者HLA抗体最敏感的技术，它开创了一种确定供体和受体之间HLA相容性的新策略。此外，所有检测到的抗HLA抗体的临床相关性尚未得到充分了解，因为该技术被证明容易出现许多假象或干扰，给生物学家和临床医生的解读带来了复杂性。本文的目的是对这种固相检测进行仔细考量，并关注有关技术性能和结果解读方面提出的问题。我们应该记住，我们的结果可能会改变致敏患者的临床管理、他们接受移植的适宜性以及后续随访情况。
